{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T18:38:27Z","timestamp":1776451107817,"version":"3.51.2"},"reference-count":33,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science (JSPS) KAKENHI","doi-asserted-by":"publisher","award":["JP20K16095"],"award-info":[{"award-number":["JP20K16095"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Voriconazole is an antifungal drug used to treat invasive aspergillosis. Voriconazole exhibits nonlinear behavior and considerable individual variability in its pharmacokinetic profile. Invasive aspergillosis has a poor prognosis, and failure of treatment owing to low voriconazole blood levels is undesirable. Thus, therapeutic drug monitoring (TDM) of voriconazole is recommended. However, plasma voriconazole concentration is rarely measured in hospitals, and the TDM of voriconazole is not widely practiced in Japan. We aimed to develop an ultra-simple method to measure plasma voriconazole concentration. Ten microliters of plasma sample was extracted, and proteins were precipitated using methanol extraction. Voriconazole and ketoconazole (internal standard) were separated using high-performance liquid chromatography. A calibration curve was prepared, which was linear over plasma voriconazole concentrations of 0.125\u201312.5 \u00b5g\/mL, with a coefficient of determination of 0.9999. The intra-day and inter-day validation coefficients were 0.9\u20132.2% and 1.3\u20136.1%, respectively. The assay accuracy was \u22124.2% to 1.6%, and recovery was &gt;97.8%. Our ultra-simple, sensitive, and inexpensive high-performance liquid chromatography ultraviolet method to determine plasma voriconazole concentration will help improve the voriconazole TDM implementation rate and contribute to effective and safe voriconazole use.<\/jats:p>","DOI":"10.3390\/jof8101035","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T23:09:29Z","timestamp":1664492969000},"page":"1035","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["High-Performance Liquid Chromatography for Ultra-Simple Determination of Plasma Voriconazole Concentration"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0587-0091","authenticated-orcid":false,"given":"Takeo","family":"Yasu","sequence":"first","affiliation":[{"name":"Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan"},{"name":"Bokutoh Hospital-Meiji Pharmaceutical University Joint Research Center, 4-23-15, Kotobashi, Sumida-ku, Tokyo 130-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8826-2296","authenticated-orcid":false,"given":"Yoshito","family":"Gando","sequence":"additional","affiliation":[{"name":"Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0796-2304","authenticated-orcid":false,"given":"Yasuhiko","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sugita","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuharu","family":"Kosugi","sequence":"additional","affiliation":[{"name":"Department of Haematology, Tokyo Metropolitan Bokutoh Hospital, 4-23-15, Kotobashi, Sumida-ku, Tokyo 130-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9194-9320","authenticated-orcid":false,"given":"Masayuki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Haematology, Tokyo Metropolitan Bokutoh Hospital, 4-23-15, Kotobashi, Sumida-ku, Tokyo 130-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijantimicag.2014.07.013","article-title":"Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections","volume":"44","author":"Wang","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jac\/dkw349","article-title":"Voriconazole metabolism is influenced by severe inflammation: A prospective study","volume":"72","author":"Veringa","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1080\/10428194.2017.1300897","article-title":"Serum C-reactive protein levels affect the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients","volume":"58","author":"Yasu","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: A randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: A meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","article-title":"Practice guidelines for therapeutic drug monitoring of vancomycin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"19","author":"Matsumoto","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1128\/AAC.47.7.2348-2350.2003","article-title":"Development and validation of a high-performance liquid chromatography assay for voriconazole","volume":"47","author":"Pennick","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jchromb.2007.01.021","article-title":"Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection","volume":"852","author":"Chhun","year":"2007","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.clinbiochem.2007.07.024","article-title":"Measurement of voriconazole in serum and plasma","volume":"40","author":"Langman","year":"2007","journal-title":"Clin. Biochem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1128\/AAC.00213-09","article-title":"Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography","volume":"53","author":"Kahle","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.clinbiochem.2011.11.004","article-title":"Rapid simultaneous determination of voriconazole and its N-oxide in human plasma using an isocratic high-performance liquid chromatography method and its clinical application","volume":"45","author":"Yamada","year":"2012","journal-title":"Clin. Biochem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1128\/AAC.01276-09","article-title":"Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry","volume":"54","author":"Farowski","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cca.2012.01.008","article-title":"Fast and simple LC\u2013MS\/MS method for quantifying plasma voriconazole","volume":"413","author":"Pauwels","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e3803","DOI":"10.1002\/bmc.3803","article-title":"A rapid MCM-41 dispersive micro-solid phase extraction coupled with LC\/MS\/MS for quantification of ketoconazole and voriconazole in biological fluids","volume":"31","author":"Yahaya","year":"2017","journal-title":"Biomed. Chromatogr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clinbiochem.2019.06.003","article-title":"Experience with therapeutic drug monitoring of three antifungal agents using an LC-MS\/MS method in routine clinical practice","volume":"70","author":"Yoon","year":"2019","journal-title":"Clin. Biochem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cca.2018.07.022","article-title":"A rapid ultra-performance LC-MS\/MS assay for determination of serum unbound fraction of voriconazole in cancer patients","volume":"486","author":"Li","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/myc.13129","article-title":"Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study conducted in Japan","volume":"63","author":"Hamada","year":"2020","journal-title":"Mycoses"},{"key":"ref_23","first-page":"53","article-title":"National survey of therapeutic drug monitoring of antimicrobial agents and antifungal agents","volume":"24","author":"Satoh","year":"2009","journal-title":"Jpn. J. Environ. Infect."},{"key":"ref_24","unstructured":"Miyai, T., Imai, S., Momo, K., Kashiwagi, H., Sato, Y., Sugawara, M., and Takekuma, Y. (2021). Implementation Status of Voriconazole Therapeutic Drug Monitoring: Analysis of Data from a Large Japanese Health Insurance Claims Database, Japanese Society of Therapeutic Drug Monitoring."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"106180","DOI":"10.1016\/j.ijantimicag.2020.106180","article-title":"Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices","volume":"56","author":"Imani","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"327","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_28","unstructured":"United States Department of Health and Human Services Food and Drug Administration (2022, April 01). In Bioanalytical Method Validation Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.05761-11","article-title":"Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults","volume":"56","author":"Friberg","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bcp.13401","article-title":"Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children","volume":"84","author":"Allegra","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Rivero-Menendez, O., Alastruey-Izquierdo, A., Mellado, E., and Cuenca-Estrella, M. (2016). Triazole resistance in Aspergillus spp.: A worldwide problem?. J. Fungi, 2.","DOI":"10.3390\/jof2030021"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/8\/10\/1035\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:42:14Z","timestamp":1760143334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/8\/10\/1035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["jof8101035"],"URL":"https:\/\/doi.org\/10.3390\/jof8101035","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]}}}